• About us
• Contact

Advertisement

Organisation › Details

GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)

GlaxoSmithKline- one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. *

 

	Start	2000-12-27 merged
	End	2022-05-16 renamed
	Group	GSK (Group)
	Today	GSK plc (LSE: GSK, NYSE: GSK)
	Predecessor	Glaxo Wellcome plc
	Successor	GSK plc (LSE: GSK, NYSE: GSK)
	Industry	pharmaceutical
	Industry 2	vaccine
	Person	Walmsley, Emma (GSK 201704– CEO before CEO of GSK Consumer Healthcare division joined GSK 2010 from L’Oréal)
	Person 2	Mackay, Iain (GSK 201901– CFO before HSBC + GE + Schlumberger Dowell + Price Waterhouse)
	Region	United Kingdom (town unspecified)
	Country	United Kingdom (GB)
	Street	980 Great West Road
	City	TW8 9GS Brentford, Middlesex
	Tel	+44-20-8742-4300
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	GBP
	Annual sales	22,716,000,000 (turnover, consolidated (2007) 2007-12-31)
	Profit	7,931,000,000 (2007-12-31)
	Cash	3,379,000,000 (2007-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for GSK (Group)

• [1] Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion"....
• [2] GSK plc. (1/9/24). "Press Release: GSK Enters Agreement to Acquire Aiolos Bio"....
• [3] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
• [4] GSK plc. (12/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20093". London....
• [5] Aiolos Bio, Inc.. (10/24/23). "Press Release: Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody". San Francisco, CA & London....
• [6] GSK plc. (10/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20089". London....
• [7] LimmaTech Biologics AG. (7/20/23). "Press Release: GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine". Schlieren....
• [8] GSK plc. (6/28/23). "Press Release: GSK Completes Acquisition of Bellus Health [For media and investors only]". London....
• [9] GSK plc. (4/18/23). "Press Release: GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company Bellus Health [For media and investors only]". London....
• [10] CureVac N.V.. (1/6/23). "Press Release: CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs". Tübingen & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.